## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### **HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

### **Equality impact assessment – Guidance development**

# STA panobinostat for treating multiple myeloma after at least 2 previous treatments

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1.	Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?
No ed	quality issues were raised during consultation or the scoping workshop.
2.	Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?
No	
3.	Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?
No	
4.	Do the preliminary recommendations make it more difficult in practice

Technology appraisals: Guidance development

the specific group?

Equality impact assessment for the panobinostat for treating multiple myeloma after at least 2

for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for

previous treatments

Issue date: November 2015

No	
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	
6.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
NA	
7.	Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No	
	oved by Associate Director (name):Frances Sutcliffe

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equalities issues were identified during the consultation

previous treatments

Issue date: November 2015

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
NA	
3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
NA	
4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
NA	
5.	Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
NA	

Date: 25/11/2015

previous treatments

Issue date: November 2015